Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NYM032 in prostate cancer
NCT06389695Phase 2Completed
- Sponsor
- Norroy Bioscience
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-NYM032 in prostate cancer (PCa), sponsored by Norroy Bioscience. Primary endpoint: Incidence of Adverse Events at 5 days. Started Jun 2024; status: completed.
02
Drugs
68Ga-NYM032
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06389695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389695.